Investigation of AhR Ligands on FcGamma Receptor Signaling: Consequences of Antibody Suppression

AhR 配体对 FcGamma 受体信号转导的研究:抗体抑制的后果

基本信息

项目摘要

ABSTRACT: It is well known that TCDD and other aryl hydrocarbon receptor (AhR) ligands suppress antibody production but there is little information about the consequences of decreased antibody production on signaling through Fcg receptors (FcgR). FcgRs are expressed on several cell types and upon being bound by IgG antibodies (and their subtypes, such as IgG1 or IgG3), initiate various effector functions including opsonization, neutralization, agglutination, complement activation, and activation of antibody-dependent cell-mediated cytotoxicity (ADCC). Thus, IgG and its subtypes play critical roles in the immune response to pathogens and in autoimmune diseases. Since TCDD and other AhR ligands have been shown to suppress IgG antibody levels, there is potential for AhR ligands to attenuate IgG-mediated effector function. Thus, the overall goal of this R15 is to connect the relatively well-characterized effects of AhR ligands on IgG antibody production with the understudied effects of AhR ligands on signaling on target cells bearing FcgR. We will test the hypothesis that AhR ligand-induced suppression of IgG antibody production leads to suppression of antibody-dependent immune responses. The hypothesis will be tested with three specific aims (SAs). SA1 is to characterize the mechanisms by which AhR ligands suppress human IgG antibody production. SA2 is to evaluate the direct effect of AhR ligands on FcgR-stimulated cells. SA3 is to evaluate the effect of AhR ligand-treated B cells to stimulate FcgR- expressing cells. Results from these studies will provide important information on the mechanism by which TCDD is immunotoxic and might also identify other non-toxic AhR ligands that have the potential to be effective therapies for autoimmune diseases.
摘要: 众所周知,TCDD和其它芳烃受体(AhR)配体抑制抗体产生,但 关于抗体产生减少对通过Fcg的信号传导的影响的信息很少 受体(FcgR)。FcgR在几种细胞类型上表达,并且在被IgG抗体结合后表达(以及它们的结合)。 亚型,如IgG 1或IgG 3),启动各种效应子功能,包括调理作用,中和, 凝集、补体激活和抗体依赖性细胞介导的细胞毒性(ADCC)的激活。 因此,IgG及其亚型在对病原体的免疫应答和自身免疫性疾病中起关键作用。 由于TCDD和其他AhR配体已被证明可以抑制IgG抗体水平,因此AhR有可能 配体以减弱IgG介导的效应子功能。因此,该R15的总体目标是连接相对 AhR配体对IgG抗体产生的充分表征的作用, 配体对携带FcgR的靶细胞上的信号传导的影响。我们将检验AhR配体诱导的 IgG抗体产生的抑制导致抗体依赖性免疫抑制 应答该假设将通过三个特定目标(SA)进行检验。SA 1是表征机制 AhR配体通过其抑制人IgG抗体产生。SA2是评价AhR的直接作用 FcgR刺激的细胞上的配体。SA 3是为了评估AhR配体处理的B细胞刺激FcgR的作用。 表达细胞。这些研究的结果将提供重要的信息, TCDD具有免疫毒性,也可能识别出其他可能有效的无毒AhR配体 自身免疫性疾病的治疗方法

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
TCDD attenuates EAE through induction of FasL on B cells and inhibition of IgG production.
  • DOI:
    10.1016/j.tox.2020.152646
  • 发表时间:
    2021-01-30
  • 期刊:
  • 影响因子:
    4.5
  • 作者:
    Kummari E;Rushing E;Nicaise A;McDonald A;Kaplan BLF
  • 通讯作者:
    Kaplan BLF
Isolation of Transcriptomic-Quality Total RNA from Mouse Spinal Cords.
  • DOI:
    10.1002/cpz1.338
  • 发表时间:
    2022-01
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Stokes JV;Nicaise AJ;Frodella CM;Varela-Stokes AS;Thompson T;Kaplan BLF
  • 通讯作者:
    Kaplan BLF
Potential for TCDD to induce regulatory functions in B cells as part of the mechanism for T cell suppression in EAE.
  • DOI:
    10.1016/j.taap.2022.116259
  • 发表时间:
    2022-11-01
  • 期刊:
  • 影响因子:
    3.8
  • 作者:
    McDonald, Amye;Nicaise, Ashleigh;Sears, Erin Rushing;Bell, Abigail;Kummari, Evangel;Kaplan, Barbara L. F.
  • 通讯作者:
    Kaplan, Barbara L. F.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Barbara Lee-Faubert Kaplan其他文献

Barbara Lee-Faubert Kaplan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Barbara Lee-Faubert Kaplan', 18)}}的其他基金

TCDD-treated B Cells Modulate T Effector and T Regulatory Function in EAE
TCDD 处理的 B 细胞调节 EAE 中的 T 效应子和 T 调节功能
  • 批准号:
    9231554
  • 财政年份:
    2017
  • 资助金额:
    $ 41.99万
  • 项目类别:
Summer Research Experience for Veterinary Students
兽医学生暑期研究经历
  • 批准号:
    10614925
  • 财政年份:
    2000
  • 资助金额:
    $ 41.99万
  • 项目类别:
Summer Research Experience for Veterinary Students
兽医学生暑期研究经历
  • 批准号:
    10333850
  • 财政年份:
    2000
  • 资助金额:
    $ 41.99万
  • 项目类别:

相似海外基金

Point-of-Care Device for Microfluidic Quantification of Agglutination
用于凝集微流体定量的护理点设备
  • 批准号:
    563571-2021
  • 财政年份:
    2021
  • 资助金额:
    $ 41.99万
  • 项目类别:
    University Undergraduate Student Research Awards
Microfluidic Agglutination Quantification Through Deep Learning
通过深度学习进行微流控凝集定量
  • 批准号:
    553149-2020
  • 财政年份:
    2020
  • 资助金额:
    $ 41.99万
  • 项目类别:
    University Undergraduate Student Research Awards
A portable agglutination test with automated serial dilution for COVID-19 infection and immunity
具有自动连续稀释功能的便携式凝集测试,用于检测 COVID-19 感染和免疫
  • 批准号:
    554378-2020
  • 财政年份:
    2020
  • 资助金额:
    $ 41.99万
  • 项目类别:
    Alliance Grants
SBIR Phase II: Developing a Platform for Multiplexed Drug Profiling Using Yeast Synthetic Agglutination
SBIR 第二阶段:开发利用酵母合成凝集进行多重药物分析的平台
  • 批准号:
    1950992
  • 财政年份:
    2020
  • 资助金额:
    $ 41.99万
  • 项目类别:
    Standard Grant
SBIR Phase I: Developing a Platform for Multiplexed Drug Profiling Using Yeast Synthetic Agglutination
SBIR 第一阶段:开发利用酵母合成凝集进行多重药物分析的平台
  • 批准号:
    1819398
  • 财政年份:
    2018
  • 资助金额:
    $ 41.99万
  • 项目类别:
    Standard Grant
SBIR Phase II: Development of an ultrasensitive, high-throughput autoantibody discovery platform using agglutination-PCR
SBIR 第二阶段:使用凝集 PCR 开发超灵敏、高通量自身抗体发现平台
  • 批准号:
    1758698
  • 财政年份:
    2018
  • 资助金额:
    $ 41.99万
  • 项目类别:
    Standard Grant
SBIR Phase I: Development of an ultrasensitive, high-throughput autoantibody discovery platform using agglutination-PCR
SBIR 第一阶段:使用凝集 PCR 开发超灵敏、高通量自身抗体发现平台
  • 批准号:
    1622257
  • 财政年份:
    2016
  • 资助金额:
    $ 41.99万
  • 项目类别:
    Standard Grant
Antibody-Detection-by-Agglutination-PCR (ADAP): An Ultra-Sensitive, High-Throughput, Multiplexable Tool for T1D Diagnosis and Monitoring
凝集 PCR 抗体检测 (ADAP):一种用于 T1D 诊断和监测的超灵敏、高通量、可多重工具
  • 批准号:
    9185244
  • 财政年份:
    2016
  • 资助金额:
    $ 41.99万
  • 项目类别:
Developing a Z-domain based latex agglutination assay for C. difficile toxins
开发基于 Z 结构域的艰难梭菌毒素乳胶凝集测定
  • 批准号:
    8831924
  • 财政年份:
    2015
  • 资助金额:
    $ 41.99万
  • 项目类别:
Molecular basis and intervention of Staphylococcus aureus agglutination
金黄色葡萄球菌凝集的分子基础及干预
  • 批准号:
    8817809
  • 财政年份:
    2014
  • 资助金额:
    $ 41.99万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了